New pdl2 compounds

Abstract

The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.

1 - 15 . (canceled) 
     
     
         16 . A peptide fragment of a human PDL2 protein of SEQ ID NO: 1, which fragment is up to 100 amino acids in length and wherein the peptide fragment comprises or consists of a consecutive sequence in a range from 8 to 100 amino acids of SEQ ID NO: 1; or a pharmaceutically acceptable salt thereof. 
     
     
         17 . The peptide fragment of  claim 16 , wherein the peptide fragment comprises or consists of a consecutive sequence in the range from 10 to 100 amino acids, such as from 10 to 17 amino acids, 20 to 30 amino acids, 30 to 40 amino acids, or from 40 to 50 amino acids. 
     
     
         18 . The peptide fragment of  claim 16 , wherein the peptide fragment does not comprise amino acids 1-3 of SEQ ID NO 1. 
     
     
         19 . The peptide fragment of  claim 16 , wherein the consecutive sequence comprises one or more sequences selected from any one of SEQ ID NO 11, 2, 4, and 12. 
     
     
         20 . The peptide fragment of  claim 16 , wherein the consecutive sequence comprises SEQ ID NO 11. 
     
     
         21 . The peptide fragment of  claim 16 , wherein the consecutive sequence comprises SEQ ID NO 4. 
     
     
         22 . The peptide fragment of  claim 16 , wherein the peptide fragment is up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids in length. 
     
     
         23 . The peptide fragment of  claim 16 , wherein the peptide fragment is an isolated, immunogenic peptide fragment. 
     
     
         24 . A composition comprising the peptide fragment of  claim 16 , optionally together with a pharmaceutically acceptable additive, such as a carrier or adjuvant. 
     
     
         25 . The composition of  claim 24 , wherein an adjuvant is present and is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants, imidazochinilines, a Montanide ISA adjuvant. 
     
     
         26 . A nucleic acid encoding the peptide fragment of  claim 16 . 
     
     
         27 . A vector comprising the nucleic acid of  claim 26 . 
     
     
         28 . A method of treating or preventing cancer in a patient, the method comprising administering to the cancer patient an effective amount of a peptide fragment of a human PDL2 protein of SEQ ID NO: 1, which fragment is up to 100 amino acids in length and wherein the peptide fragment comprises or consists of a consecutive sequence in a range from 8 to 100 amino acids of SEQ ID NO: 1; or a pharmaceutically acceptable salt thereof; or a nucleic acid comprising said peptide fragment; or a vector comprising a nucleic acid encoding said peptide fragment. 
     
     
         29 . The method of  claim 28  wherein:
 (a) the peptide fragment comprises or consists of a consecutive sequence in the range from 10 to 100 amino acids, such as from 10 to 17 amino acids, 20 to 30 amino acids, 30 to 40 amino acids, or from 40 to 50 amino acids; and/or 
 (b) the peptide fragment does not comprise amino acid 1-3 of SEQ ID NO 1; and/or 
 (c) the consecutive sequence comprises one or more sequences selected from any one of SEQ ID NO 11, 2, 4, and 12; and/or 
 (d) the peptide fragment is up to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids in length; and/or 
 (e) the peptide fragment is an isolated, immunogenic peptide fragment. 
 
     
     
         30 . The method of  claim 28 , wherein the consecutive sequence comprises or consists of SEQ ID NO 11. 
     
     
         31 . The method of  claim 28 , wherein the consecutive sequence comprises or consists of SEQ ID NO 4. 
     
     
         32 . The method of  claim 28 , wherein the method further comprises the simultaneous or sequential administration of an additional cancer therapy, such as a cytokine therapy, a T-cell therapy, an NK therapy, an immune system checkpoint inhibitor, chemotherapy, radiotherapy, immunostimulating substances, gene therapy, antibodies and dendritic cells. 
     
     
         33 . The method of  claim 32 , wherein the additional cancer therapy is selected from one or more of Actimide, Azacitidine, Azathioprine, Bleomycin, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Irinotecan, Lenalidomide, Leucovorin, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitoxantrone, Nivolumab, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Revlimid, Temozolomide, Teniposide, Thioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine and Vinorelbine. 
     
     
         34 . The method of  claim 28 , wherein the cancer is selected from the group consisting of melanoma, renal cell carcinoma, non-hodgkin lymphoma, and ovarian cancer. 
     
     
         35 . The method of  claim 28 , wherein the cancer is characterized by expression of PDL2.